Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Melissa R. Mazan has a total of 66 co-authors. Here are the top co-authors by number of shared publications:

  • Daniela Bedenice

    Department of Large Animal Clinical Sciences, Cummings School of Veterinary Medicine at Tufts University, North Grafton, MA 01536, United States

    6 shared publications
  • Andrew M. Hoffman

    Department of Clinical Sciences, Cummings School of Veterinary Medicine, Tufts University, Massachusetts, USA

    5 shared publications
  • Daniela Bedenice

    Department of Clinical Sciences, Cummings School of Veterinary Medicine at Tufts University, Grafton, Massachusetts, United States

    5 shared publications
  • Edward F. Deveney

    Department of Physics, Photonics, and Optical Engineering, Bridgewater State University, Bridgewater, Massachusetts, United States

    4 shared publications
  • Ananya Mahalingam-Dhingra

    Clinical Sciences, Cummings School of Veterinary Medicine at Tufts University , North Grafton, MA 01536

    3 shared publications
  • Andrew Hoffman

    2 shared publications

Latest Publications

  • Open Access

    Clinical and microbiota alterations in performance horses undergoing long-distance transport.

    by Ananya Mahalingam-Dhingra, Daniela Bedenice, Debora Regina Romualdo da Silva, Melissa Mazan, Tiffany Hall, Wade Tenney, Giovanni Widmer

    Transport-associated pneumonia contributes substantially to morbidity, impaired welfare, and economic loss in high-performance horses and may be associated with alterations in the respiratory microbiota. Examine the effect of long-distance transport on the respiratory microbiota and correlate changes in microbiota diversity and composition with systemic and airway inflammation. Seventeen client-owned performance horses transported from New England to Florida under optimized trailering conditions, and 12 non-traveling horses. Physical examination, blood testing, nasopharyngeal wash, endoscopy, tracheal aspirates, and thoracic ultrasonography were performed 48 h before, and 24 and 72 h after transport (T1-T3). Upper and lower respiratory microbiota were characterized using high-throughput 16S rRNA sequencing and correlated with clinical variables using constrained ordination. Transport effects were evaluated using repeated measures analysis of variance (ANOVA). Cortisol concentrations decreased post-transport (P = .02), whereas ultrasound scores (P = .01) and serum amyloid A concentrations (P = .03) increased from T1 to T3. Timepoint explained a small but significant portion of microbiota variability (P < .001). Upper and lower airway microbiota differed, with the lower airway showing more β diversity (lower stability; P < .001). Together, timepoint and ultrasound scores explained 19% and 10%, respectively, of nasal and tracheal bacterial microbiota variability. Operational taxonomic units with the highest fit to timepoint and ultrasound were enriched for plant-associated bacterial taxa, mainly Hyphomicrobiales. Even under standardized, optimized transport conditions, respiratory microbiota alterations occurred in healthy, athletic horses, correlating with ultrasonographic evidence of pulmonary inflammation. Inclusion of the fungal mycobiome may further improve our understanding of transport-associated respiratory disease.


  • Open Access

    An in-hospital clinical trial assessing nebulized lidocaine compared to saline for treatment of asthma in horses

    by Ananya Mahalingam-Dhingra, Daniela Bedenice, Adam South, Jillian Minuto, Tyler-Jane Robins, Victoria Trautwein, Melissa Larkin, Bettina Wagner, Melissa R Mazan

    Background: Corticosteroids are the main pharmacologic treatment for equine asthma (EA) but may have adverse effects in metabolically unstable horses. Recent pilot studies support the use of nebulized lidocaine as an alternative treatment option. Hypothesis/Objectives: Nebulized lidocaine will improve EA-associated clinical variables and airway inflammation. Animals: Twenty client-owned horses diagnosed with EA. Methods: Randomized, blinded, in-hospital study comparing 1 mg/kg preservative-free 4% lidocaine (n = 10) nebulized via Flexineb (twice daily for 7 doses) to 0.9% saline control (n = 10). Clinical examination, endoscopy, lung function, bronchoalveolar lavage (BAL) cytology, and inflammatory cytokines in blood and epithelial lining fluid (ELF) were compared between treatment groups using univariate analyses. Global linear models were used to assess covariate impact (P < .05). Results: The effect of treatment on clinical variables (clinical score, lung function, mucus, and BAL cytology) did not differ between saline and lidocaine treated horses. However, the severity of EA as a covariate significantly impacted multiple baseline variables and confounded the effect of treatment type. Saline-treated horses showed significantly larger decreases in ELF tissue necrosis factor alpha (P = .04) and interferon gamma concentrations (P = .03), compared with lidocaine-treated horses, independent of covariates. Conclusions and clinical importance: We did not identify a difference in treatment effect of nebulized lidocaine compared to saline on clinical variables in hospitalized asthmatic horses. A longer duration of lidocaine administration or focus on severe EA may be necessary to establish treatment effects. Observed changes in lower airway cytokine concentrations suggest that saline may have more than a placebo effect in treating EA.


  • Flow interruption compared to forced oscillatory maneuvers and esophageal balloon/pneumotachography for measurement of respiratory resistance in the horse

    by Melissa R. Mazan, Christopher Simotas, Thomas Coons, Brian Barrow, Daniela Bedenice, Jill Minuto, Kristen Wendell, Edward F. Deveney

    We developed and document for the first time the use of flow interruption for the rapid and noninvasive measurement of resistance in equine patients and demonstrated short- and long-term stability and accuracy in comparison with the reference methods.

  • Open Access

    A cross-sectional observational study of birefringent particulates in bronchoalveolar lavage cytology in horses with equine asthma from the West v East coasts of the USA

    by Melissa R. Mazan, Edward F. Deveney

    Equine asthma (EA) is an important cause of wastage in the USA horse industry. Exposure to organic particulates, from stable dust, airborne pollen, and fungal loads, is posited to be the main cause. Dust arising from the earth’s crust has been largely ignored as a contributor to EA in the veterinary literature. The objectives of this study were to investigate the occurrence of birefringent particulates in the bronchoalveolar lavage fluid (BALF) of horses with a clinical complaint of EA residing in the arid West of the USA v. the East, in an effort to determine the contribution of geolocation to geogenic dust exposure. We analyzed BALF cytology and historical data sent to our referral clinical laboratory from 148 horses from the West Coast and 233 horses from the East Coast of the USA over a 6-year period, using light microscopy to determine cell proportions and other visible elements as well as a polarizing lens to detect birefringent material. Univariate analysis showed that horses from the West coast were significantly more likely to have birefringent particulates in the BALF than horses from the East coast (40.5% v. 8.6%, p < 0.001); while horses from the East had higher BALF neutrophil proportions. Horses from the West also had lower proportions of neutrophils in the BALF than those from the East (27.1 v. 10.9, p < .001). Using historical and BAL data in a forward stepwise binary logistic regression model with presence of birefringent particulates found within alveolar macrophages as the outcome, geographical location in the West retained significance as a predictor (OR 8.0, CI [4.3–14.8], p< .001). While the birefringent particulates cannot be identified on the basis of polarizing microscopy alone, this study provides evidence that horses from the West are exposed to inorganic particulates that may contribute to signs of equine asthma.


  • Open Access

    A Longitudinal Analysis of Equine Asthma Presentation and Response to Treatment Using Lung Function Testing and BAL Cytology Analysis in Combination with Owner Perception

    by Tyler-Jane Robins, Daniela Bedenice, Melissa Mazan

    (1) Background: Equine asthma (EA) is a pervasive and important cause of poor performance and respiratory morbidity in horses. Diagnosis of EA includes an owner complaint, clinical scoring, lung function testing, and cytological analysis of bronchoalveolar lavage (BAL) cytology. There is a paucity of information about the longitudinal course of the disease using these outcome assessments; thus, this study sought to describe and quantify, in horses with more than one visit to a specialty pulmonary clinic in New England, the type and range of clinical presentations with an eventual diagnosis of EA. It also aimed to develop and compare the outcomes of scoring systems for owner complaints and veterinary assessments, document and assess the diagnostic methods used, and evaluate the response of the horses to treatment and time. (2) Methods: This study was a retrospective, cross-sectional, STROBE-compliant observational analysis of equine patients who visited the Tufts Cummings Hospital for Large Animals (HLA) for evaluation of equine asthma (EA) from 1999–2023. The horses were categorized as having mild–moderate (mEA) or severe EA (sEA) using the ACVIM consensus statement guidelines. After excluding those with inadequate documentation or only one visit (n = 936), a total of 76 horses were included in the study. Of the 197 visits, 138 (70.0%) resulted in a diagnosis of mEA and 45 (22.8%) resulted in a diagnosis of sEA. Demographic information, owner complaints, clinical examination and scoring, lung function testing, BAL cytology, and recommendations for environmental remediation and pharmacologic treatment were recorded for all the visits. The data were analyzed for agreement between owner complaints (complaint score, CS) and clinical examination findings (examination score, ES), changes in CS and ES, lung function testing, and BAL cytology over time, with 197 visits recorded. (3) Results: A comparison between the CS and ES showed that the owners were more likely than veterinarians to detect cough, and a decrease in cough was the most common owner observation after treatment. The response to the histamine challenge, used to detect airway hyperreactivity, was significantly improved with treatment or time in the horses with mEA, whereas baseline lung function did not significantly change in mEA or sEA. (4) Conclusions: Owners can be astute observers of clinical signs, especially cough, in EA. Tests of airway hyperreactivity are more successful in detecting changes in mEA than are baseline lung function testing and assessment of BAL cytology.


  • Open Access

    Bronchoalveolar lavage hemosiderosis in lightly active or sedentary horses

    by Ananya Mahalingam-Dhingra, Daniela Bedenice, Melissa R. Mazan

    Background: Hemosiderophages in bronchoalveolar lavage fluid (BALF) are commonly ascribed to exercise-induced pulmonary hemorrhage (EIPH). Little information exists regarding the presence of these cells in horses that perform light or no work and that are referred for respiratory problems. Objectives: Evaluate the presence of hemosiderophages in BALF of horses suspected of respiratory disease without history of or risk factors for EIPH and determine predictors of hemosiderophages in BALF in this population. Methods: Observational retrospective cross-sectional study using STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines. Bronchoalveolar lavage fluid cytology reports of 353 horses evaluated for respiratory disease between 2012 and 2022 at the Cummings School for Veterinary Medicine were reviewed retrospectively. Horses with a history or likelihood of having performed past strenuous exercise were removed, and the remaining 91 horses were divided into hemosiderin-positive (HSD-POS) and hemosiderin-negative groups based on Perls' Prussian blue staining. Potential predictors for the presence of hemosiderophages in BALF (history, clinical evaluation, baseline lung function, airway reactivity, BALF cytology, and hemosiderin score) were compared between the 2 groups, using univariate and multivariate analyses. Results: Horses with a diagnosis of severe equine asthma (sEA; odds ratio, 11.1; 95% confidence interval, 3.2-38.5; P < .001) were significantly more likely to be HSD-POS than horses with mild-to-moderate equine asthma. Conclusions and Clinical Importance: Hemosiderophages were found in the BALF cytology in a subset of horses that perform light or no work and presented for respiratory signs; these cells were found more frequently in horses with sEA. The link between hemosiderophages and sEA highlights previously unstudied pathology associated with this common disease.


  • Open Access

    Clinical effects and pharmacokinetics of nebulized lidocaine in healthy horses

    by Jillian Minuto, Daniela Bedenice, Michelle Ceresia, Iman Zaghloul, Mark Böhlke, Melissa R. Mazan

    Background: Nebulized lidocaine appears promising as a novel corticosteroid-sparing therapeutic for equine asthma, but its safety and pharmacokinetic behavior have yet to be confirmed.Objective: To describe the effect of nebulized lidocaine on upper airway sensitivity, lung mechanics, and lower respiratory cellular response of healthy horses, as well as delivery of lidocaine to lower airways, and its subsequent absorption, clearance, and duration of detectability.Animals: Six healthy university- and client-owned horses with normal physical examination and serum amyloid A, and no history of respiratory disease within 6 months.Methods: Prospective, descriptive study evaluating the immediate effects of 1 mg/kg 4% preservative-free lidocaine following nebulization with the Flexineb®. Prior to and following nebulization, horses were assessed using upper airway endoscopy, bronchoalveolar lavage, and pulmonary function testing with esophageal balloon/pneumotachography and histamine bronchoprovocation. Additionally, blood and urine were collected at predetermined times following single-dose intravenous and nebulized lidocaine administration for pharmacokinetic analysis.Results: Upper airway sensitivity was unchanged following lidocaine nebulization, and no laryngospasm or excessive salivation was noted. Lidocaine nebulization (1 mg/kg) resulted in a mean epithelial lining fluid concentration of 9.63 ± 5.05 μg/mL, and a bioavailability of 29.7 ± 7.76%. Lidocaine concentrations were higher in epithelial lining fluid than in systemic circulation (Cmax149.23 ± 78.74 μg/L, CELF:Cmaxplasma64.4, range 26.5–136.8). Serum and urine lidocaine levels remained detectable for 24 and 48 h, respectively, following nebulization of a single dose. Baseline spirometry, lung resistance and dynamic compliance, remained normal following lidocaine nebulization, with resistance decreasing post-nebulization. Compared to the pre-nebulization group, two additional horses were hyperresponsive following lidocaine nebulization. There was a significant increase in mean airway responsiveness post-lidocaine nebulization, based on lung resistance, but not dynamic compliance. One horse had BAL cytology consistent with airway inflammation both before and after lidocaine treatment.Conclusions: Nebulized lidocaine was not associated with adverse effects on upper airway sensitivity or BAL cytology. While baseline lung resistance was unchanged, increased airway reactivity to histamine bronchoprovocation in the absence of clinical signs was seen in some horses following nebulization. Further research is necessary to evaluate drug delivery, adverse events, and efficacy in asthmatic horses.


  • Open Access

    Equine exercise physiology—challenges to the respiratory system

    by Melissa Mazan

    The job of the respiratory system is, ultimately, to deliver oxygen to, and take carbon dioxide away from the rest of the body. It is important, therefore, to refresh our memories about the transport of oxygen in the body.


    • 1 April 2022
      • Vol. 86  (2) , 116-124

    A CONSORT-guided, randomized, double-blind, controlled pilot clinical trial of inhaled lidocaine for the treatment of equine asthma

    by Ananya Mahalingam-Dhingra, Melissa R. Mazan, Daniela Bedenice, Michelle Ceresia, Jill Minuto, Edward F. Deveney

    There are limited options for treatment of the common disease, equine asthma. The aim of this study was to estimate the feasibility and potential efficacy of using nebulized lidocaine for treating equine asthma, while at the same time treating a separate cohort of asthmatic horses with inhaled budesonide. Nineteen horses with a history consistent with equine asthma were recruited from our referral population for a double-blind, randomized, controlled pilot clinical trial using Consolidated Standards of Reporting Trials (CONSORT) guidelines. After screening, 16 horses met the inclusion criteria for equine asthma and 13 horses actually completed the study. Horses were treated by their owners at home for 14 d before returning to our hospital for follow-up assessment. Interventions consisted of nebulization q12h for 14 d with 1.0 mg/kg body weight (BW) of lidocaine or corticosteroid treatment (nebulized budesonide 1 mg/kg, q12h). Clinical and tracheal mucus score, pulmonary function testing, and respiratory secretion cytology were assessed after 2 weeks of treatment to determine the outcome. Both lidocaine and budesonide cohorts had significant decreases (P < 0.05) in clinical score; the lidocaine cohort showed a significant decrease in bronchoalveolar lavage (BAL) neutrophil percentage and tracheal mucus score. Neither treatment resulted in significant changes in lung function parameters. No adverse events occurred. Lidocaine may be an effective and safe treatment for equine asthma in horses that cannot tolerate treatment with corticosteroids.


  • Open Access

    Association between inflammatory airway disease of horses and exposure to respiratory viruses: a case control study

    by Ashley Houtsma, Daniela Bedenice, Nicola Pusterla, Brenna Pugliese, Samantha Mapes, Andrew M. Hoffman, Julia Paxson, Elizabeth Rozanski, Jean Mukherjee, Margaret Wigley, et al.

    Background: Inflammatory airway disease (IAD) in horses, similar to asthma in humans, is a common cause of chronic poor respiratory health and exercise intolerance due to airway inflammation and exaggerated airway constrictive responses. Human rhinovirus is an important trigger for the development of asthma; a similar role for viral respiratory disease in equine IAD has not been established yet. Methods: In a case–control study, horses with IAD (n = 24) were compared to control animals from comparable stabling environments (n = 14). Horses were classified using pulmonary function testing and bronchoalveolar lavage. PCR for equine rhinitis virus A and B (ERAV, ERBV), influenza virus (EIV), and herpesviruses 2, 4, and 5 (EHV-2, EHV-4, EHV-5) was performed on nasal swab, buffy coat from whole blood, and cells from BAL fluid (BALF), and serology were performed. Categorical variables were compared between IAD and control using Fisher’s exact test; continuous variables were compared with an independent t-test. For all analyses, a value of P <0.05 was considered significant. Results: There was a significant association between diagnosis of IAD and history of cough (P = 0.001) and exercise intolerance (P = 0.003) but not between nasal discharge and IAD. Horses with IAD were significantly more likely to have a positive titer to ERAV (68 %) vs. control horses (32 %). Horses with IAD had higher log-transformed titers to ERAV than did controls (2.28 ± 0.18 v.1.50 ± 0.25, P = 0.038). There was a significant association between nasal shedding (positive PCR) of EHV-2 and diagnosis of IAD (P = 0.002). Conclusions: IAD remains a persistent problem in the equine population and has strong similarities to the human disease, asthma, for which viral infection is an important trigger. The association between viral respiratory infection and development or exacerbation of IAD in this study suggests that viral infection may contribute to IAD susceptibility; there is, therefore, merit in further investigation into the relationship between respiratory virus exposure and development of IAD.